2. Search Result
Search Result
Results for "

Micrococcus+luteus

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2124
    Cyclo(L-Trp-L-Trp)

    		Antibiotic Bacterial Infection
    Cyclo(L-Trp-L-Trp) is an antibiotic, and shows antimicrobial activity. Cyclo(L-Trp-L-Trp) can inhibit A. baumannii, as well as Candida albicans, Bacillus subtilis, Micrococcus luteus, Saccharomyces cerevisiae, Aspergillus niger, Staphylococcus aureus. Cyclo(L-Trp-L-Trp) can be used in microbial infection research .
    Cyclo(L-Trp-L-Trp)
  • HY-W018629
    Antibacterial agent 265

    		Bacterial Drug Intermediate Infection
    Antibacterial agent 265 (Compound 2) is an antibacterial agent. Antibacterial agent 265 shows antibacterial activity against Staphylococcus Aureus, Micrococcus Luteus, Bacillus subtilis, gram-negative Escherichia coli, Pseudomonas aeruginosa and Flavobacterium devorans .
    Antibacterial agent 265
  • HY-N15184
    Benanomicin B

    Pradimicin C

    		 Bacterial Fungal Infection
    Benanomicin B (Pradimicin C) is an antifungal antibiotic that also has antibacterial activity against two Gram-positive bacteria: Micrococcus luteus and Corynebacterium bovis .
    Benanomicin B
  • HY-N14921
    [R-(Z)]-4-Amino-3-chloro-2-pen-tenedioicacid

    		Bacterial Infection
    [R-(Z)]-4-Amino-3-chloro-2-pen-tenedioicacid is virtually limited to Micrococcus luteus .
    [R-(Z)]-4-Amino-3-chloro-2-pen-tenedioicacid
  • HY-N8336
    IT-143A

    		Antibiotic Bacterial Fungal Infection Cancer
    IT-143A is an antibiotic, that exhibits antibacterial and antifungal activity against Micrococcus luteus and Aspergillus fumigatus with MIC of 6.25-25 μg/mL. IT-143A inhibits growth of cancer cell KB with an IC50 of 0.36 ng/mL .
    IT-143A
  • HY-N8337
    IT-143B

    		Bacterial Antibiotic Infection
    IT-143B is an antibiotic, that exhibits antibacterial activity against Micrococcus luteus with MIC of 6.25μg/mL. IT-143B inhibits growth of cancer cell KB with an IC50 of 1.1 ng/mL .
    IT-143B
  • HY-161239A
    IB-96212

    		Antibiotic Infection Cancer
    IB-96212 (compound 5) is a member of oligomycin class which can be extracted ftom the marine Micromonospora sp. L-25-ES25-008 ref. IB-96212 is an antitumor antibiotic against P-388, it also exhibits antimicrobial activity against Micrococcus luteus .
    IB-96212
  • HY-117657
    (-)-BO 2367

    		Topoisomerase Bacterial Inflammation/Immunology Cancer
    (-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC50 values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .
    (-)-BO 2367
  • HY-N14238
    Epoxyquinomicin B

    		Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Epoxyquinomicin B is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin B exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 6.25-12.5 µg/mL. Epoxyquinomicin B exhibits cytotoxicity in cancer cell L1210 with IC50 of 16.3 µg/mL. Epoxyquinomicin B exhibits anti-inflammatory effects against collagen-induced arthritis .
    Epoxyquinomicin B
  • HY-N14237
    Epoxyquinomicin A

    		Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Epoxyquinomicin A is an antibiotic that can be isolated from Amycolatopsis sp. Epoxyquinomicin A exhibits inhibitory activity against Micrococcus luteus, Bacillus subtilis, Pasteurella piscicida and Staphylococcus aureus with a MIC of 3-12.5 µg/mL. Epoxyquinomicin A exhibits cytotoxicity in cancer cell L1210, B16 and S180 with IC50 of 2-8 µg/mL. Epoxyquinomicin A exhibits anti-inflammatory effects against collagen-induced arthritis .
    Epoxyquinomicin A
  • HY-W756467
    Antibacterial agent 265-13C,d3

    1-Cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid-13C,d3

    		 Isotope-Labeled Compounds Bacterial Drug Intermediate Infection
    Antibacterial agent 265- 13C,d3 (1-Cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid- 13C,d3) is the deuterium labeled and 13C-labeled Antibacterial agent 265 (HY-W018629). Antibacterial agent 265 (Compound 2) is an antibacterial agent. Antibacterial agent 265 shows antibacterial activity against Staphylococcus Aureus, Micrococcus Luteus, Bacillus subtilis, gram-negative Escherichia coli, Pseudomonas aeruginosa and Flavobacterium devorans .
    Antibacterial agent 265-13C,d3
  • HY-N19219
    Wailupemycin F

    		Antibiotic Endogenous Metabolite Bacterial Infection Cancer
    Wailupemycin F is an Antibiotic and anticancer agent. Wailupemycin F is isolated from the marine-derived Streptomyces maritimus. Wailupemycin F exhibits antibacterial activity against Micrococcus luteus with a MIC of 1.1 μM. Wailupemycin F shows anticancer activity against myeloma. When used in combination with enterocin, Wailupemycin F exerts synergistic antibacterial activity against Micrococcus luteus, doubling its potency. Wailupemycin F can be used in studies related to Micrococcus luteus infection .
    Wailupemycin F
  • HY-164999
    N,N'-Bis(2,3-Dihydroxybenzoyl)-O-L-seryl-L-serine

    		Endogenous Metabolite Cancer
    N,N'-Bis(2,3-Dihydroxybenzoyl)-O-L-seryl-L-serine is a enterochelin hydrolyzed product. N,N'-Bis(2,3-Dihydroxybenzoyl)-O-L-seryl-L-serine can inhibit the invasion of murine colon cancer cells 26-L5 with an IC50 of 2.7 μM, and has anti-tumor effect. In addition, N,N'-Bis(2,3-Dihydroxybenzoyl)-O-L-seryl-L-serine has no appreciable antimicrobial activities against Micrococcus luteus, Escherichia coli and Candida albicans .
    N,N'-Bis(2,3-Dihydroxybenzoyl)-O-L-seryl-L-serine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: